Lupus drug hydroxychloroquine tested as COVID-19 shield

NCT ID NCT04481633

Completed Prevention Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated May 10, 2026 · Updated 17 times

Summary

This study looked at whether lupus patients already taking hydroxychloroquine were less likely to catch or get severely ill from COVID-19. Researchers compared 552 patients who were either on or off the drug. The goal was to see if the medication offered any protection during the pandemic.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Haut-Lévêque Hospital - Gastro-entérologie

Pessac, 33604, France
Haut-Lévêque Hospital - Médecine interne

Pessac, 33604, France
Joseph Ducuing Hospital - Médecine interne

Toulouse, 31027, France
Limoges university Hospital

Limoges, 87042, France
Montpellier University Hospital

Montpellier, 31295, France
Pitié Salpêtrière Hospital - Hépatologie

Paris, 75651, France
Pitié Salpêtrière Hospital - Médecine interne

Paris, 75651, France
Toulouse University Hospital

Toulouse, 31059, France
Toulouse University Hospital - Rhumatologie

Toulouse, 31059, France
Toulouse university Hospital - Larrey Dermatologie

Toulouse, 31059, France
University Hospital of Toulouse - Rangueil Médecine interne

Toulouse, 31059, France
University hospital Toulouse - Purpan Médecine interne

Toulouse, 31059, France

Conditions

Explore the condition pages connected to this study.

COVID - 19